|
1
|
Schatten H: Brief overview of prostate
cancer statistics, grading, diagnosis and treatment strategies. Adv
Exp Med Biol. 1095:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holm HV, Dahl AA, Klepp OH and Fossa SD:
Modern treatment of metastatic prostate cancer. Tidsskr Nor
Laegeforen. 137:803–805. 2017.(In English, Norwegian). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grubb RL III and Kibel AS: Prostate
cancer: Screening, diagnosis and management in 2007. Mo Med.
104:408–414. 2007.PubMed/NCBI
|
|
5
|
Gomez CR, Kosari F, Munz JM, Schreiber CA,
Knutson GJ, Ida CM, El Khattouti A, Karnes RJ, Cheville JC,
Vasmatzis G and Vuk-Pavlović S: Prognostic value of discs large
homolog 7 transcript levels in prostate cancer. PLoS One.
8:e828332013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Semenza GL: Hypoxia-inducible factors in
physiology and medicine. Cell. 148:399–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deep G and Panigrahi GK: Hypoxia-induced
signaling promotes prostate cancer progression: Exosomes role as
messenger of hypoxic response in tumor microenvironment. Crit Rev
Oncog. 20:419–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Du J, Sun B, Zhao X, Gu Q, Dong X, Mo J,
Sun T, Wang J, Sun R and Liu Y: Hypoxia promotes vasculogenic
mimicry formation by inducing epithelial-mesenchymal transition in
ovarian carcinoma. Gynecol Oncol. 133:575–583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shaikh D, Zhou Q, Chen T, Ibe JC, Raj JU
and Zhou G: cAMP-dependent protein kinase is essential for hypoxia-
mediated epithelial-mesenchymal transition, migration, and invasion
in lung cancer cells. Cell Signal. 24:2396–2406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Liu Y, Yan X, Xu Y, Luo F, Ye J,
Yan H, Yang X, Huang X, Zhang J and Ji G: HIFs enhance the
migratory and neoplastic capacities of hepatocellular carcinoma
cells by promoting EMT. Tumour Biol. 35:8103–8114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hay ED: Role of cell-matrix contacts in
cell migration and epithelial-mesenchymal transformation. Cell
Differ Dev. 32:367–375. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khan MI, Hamid A, Adhami VM, Lall RK and
Mukhtar H: Role of epithelial mesenchymal transition in prostate
tumorigenesis. Curr Pharm Des. 21:1240–1248. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cowin P, Rowlands TM and Hatsell SJ:
Cadherins and catenins in breast cancer. Curr Opin Cell Biol.
17:499–508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iwasaki K, Ninomiya R, Shin T, Nomura T,
Kajiwara T, Hijiya N, Moriyama M, Mimata H and Hamada F: Chronic
hypoxia-induced slug promotes invasive behavior of prostate cancer
cells by activating expression of ephrin-B1. Cancer Sci.
109:3159–3170. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liao GB, Li XZ, Zeng S, Liu C, Yang SM,
Yang L, Hu CJ and Bai JY: Regulation of the master regulator FOXM1
in cancer. Cell Commun Signal. 16:572018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ahmad A, Wang Z, Kong D, Ali S, Li Y,
Banerjee S, Ali R and Sarkar FH: FoxM1 down-regulation leads to
inhibition of proliferation, migration and invasion of breast
cancer cells through the modulation of extra-cellular matrix
degrading factors. Breast Cancer Res Treat. 122:337–346. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang C, Chen H, Tan G, Gao W, Cheng L,
Jiang X, Yu L and Tan Y: FOXM1 promotes the epithelial to
mesenchymal transition by stimulating the transcription of Slug in
human breast cancer. Cancer Lett. 340:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abdeljaoued S, Bettaieb I, Nasri M, Adouni
O, Goucha A, El Amine O, Boussen H, Rahal K and Gamoudi A:
Overexpression of FOXM1 is a potential prognostic marker in male
breast cancer. Oncol Res Treat. 40:167–172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Y, Yu W, Zhou L, Wu S, Yang Y, Wang
J, Tian Y, He D, Xu Y, Huang J, et al: Relationship among diet
habit and lower urinary tract symptoms and sexual function in
outpatient-based males with LUTS/BPH: A multiregional and
cross-sectional study in China. BMJ Open. 6:e0108632016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M,
Guo YH, Shi J, Gong XD, Zhu YL, Liu F, et al: Overexpression of
FOXM1 is associated with EMT and is a predictor of poor prognosis
in non-small cell lung cancer. Oncol Rep. 31:2660–2668. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ito T, Kohashi K, Yamada Y, Maekawa A,
Kuda M, Furue M and Oda Y: Prognostic significance of forkhead box
M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in
melanoma. Histopathology. 69:63–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Y, Liu Y, Yuan B, Yin L, Peng Y, Yu X,
Zhou W, Gong Z, Liu J, He L and Li X: FOXM1 promotes the
progression of prostate cancer by regulating PSA gene
transcription. Oncotarget. 8:17027–17037. 2017.PubMed/NCBI
|
|
25
|
Li L, Wu D, Yu Q, Li L and Wu P:
Prognostic value of FOXM1 in solid tumors: A systematic review and
meta-analysis. Oncotarget. 8:32298–32308. 2017.PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McCarthy DJ, Chen Y and Smyth GK:
Differential expression analysis of multifactor RNA-Seq experiments
with respect to biological variation. Nucleic Acids Res.
40:4288–4297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kalluri RJ: EMT: When epithelial cells
decide to become mesenchymal-like cells. J Clin Invest.
119:1417–1419. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grunert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang
SY, Liu CJ, Teng SC and Wu KJ: Direct regulation of TWIST by
HIF-1alpha promotes metastasis. Nat Cell Biol. 10:295–305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boddy JL, Fox SB, Han C, Campo L, Turley
H, Kanga S, Malone PR and Harris AL: The androgen receptor is
significantly associated with vascular endothelial growth factor
and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a,
and the prolyl hydroxylases in human prostate cancer. Clin Cancer
Res. 11:7658–7663. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mak P, Leav I, Pursell B, Bae D, Yang X,
Taglienti CA, Gouvin LM, Sharma VM and Mercurio AM: ERbeta impedes
prostate cancer EMT by destabilizing HIF-1alpha and inhibiting
VEGF-mediated snail nuclear localization: Implications for Gleason
grading. Cancer Cell. 17:319–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo Y, He DL, Ning L, Shen SL, Li L, Li X,
Zhau HE and Chung LW: Over-expression of hypoxia-inducible
factor-1alpha increases the invasive potency of LNCaP cells in
vitro. BJU Int. 98:1315–1319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bizzarro V, Belvedere R, Migliaro V,
Romano E, Parente L and Petrella A: Hypoxia regulates ANXA1
expression to support prostate cancer cell invasion and
aggressiveness. Cell Adh Migr. 11:247–260. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, Li
Y, Chen YT, Yin F, Liao CP, et al: Monoamine oxidase A mediates
prostate tumorigenesis and cancer metastasis. J Clin Invest.
124:2891–2908. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng WS, Tao H, Hu EP, Liu S, Cai HR, Tao
XL, Zhang L, Mao JJ and Yan DL: Both genes and lncRNAs can be used
as biomarkers of prostate cancer by using high throughput
sequencing data. Eur Rev Med Pharmacol Sci. 18:3504–3510.
2014.PubMed/NCBI
|
|
39
|
Han Y, Jin X, Li H, Wang K, Gao J, Song L
and Lv Y: Microarray analysis of copy-number variations and gene
expression profiles in prostate cancer. Medicine (Baltimore).
96:e72642017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tan J, Jin X and Wang K: Integrated
bioinformatics analysis of potential biomarkers for prostate
cancer. 25:455–460. 2019.PubMed/NCBI
|
|
41
|
Soni S and Padwad YS: HIF-1 in cancer
therapy: Two decade long story of a transcription factor.
56:503–515. 2017.PubMed/NCBI
|
|
42
|
Semenza GL: Regulation of mammalian O2
homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol.
15:551–578. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Korver W, Roose J, Heinen K, Weghuis DO,
de Bruijn D, van Kessel AG and Clevers H: The human TRIDENT/HFH-
11/FKHL16 gene: Structure, localization, and promoter
characterization. Genomics. 46:435–442. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Laoukili J, Stahl M and Medema RH: FoxM1:
At the crossroads of ageing and cancer. Biochim Biophys Acta.
1775:92–102. 2007.PubMed/NCBI
|
|
45
|
Nandi D, Cheema PS, Jaiswal N and Nag A:
FoxM1: Repurposing an oncogene as a biomarker. Semin Cancer Biol.
52:74–84. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang DK, Son CH, Lee SK, Choi PJ, Lee KE
and Roh MS: Forkhead box M1 expression in pulmonary squamous cell
carcinoma: Correlation with clinicopathologic features and its
prognostic significance. Hum Pathol. 40:464–470. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sun HC, Li M, Lu JL, Yan DW, Zhou CZ, Fan
JW, Qin XB, Tang HM and Peng ZH: Overexpression of Forkhead box M1
protein associates with aggressive tumor features and poor
prognosis of hepatocellular carcinoma. Oncol Rep. 25:1533–1539.
2011.PubMed/NCBI
|
|
48
|
Huynh KM, Soh JW, Dash R, Sarkar D, Fisher
PB and Kang D: FOXM1 expression mediates growth suppression during
terminal differentiation of HO-1 human metastatic melanoma cells. J
Cell Physiol. 226:194–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xia L, Mo P, Huang W, Zhang L, Wang Y, Zhu
H, Tian D, Liu J, Chen Z, Zhang Y, et al: The
TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes
HCC proliferation and resistance to apoptosis. Carcinogenesis.
33:2250–2259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ and
Liu WC: FoxM1 expression is significantly associated with
cisplatin-based chemotherapy resistance and poor prognosis in
advanced non-small cell lung cancer patients. Lung Cancer.
79:173–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cai Y, Balli D, Ustiyan V, Fulford L,
Hiller A, Misetic V, Zhang Y, Paluch AM, Waltz SE, Kasper S and
Kalin TV: Foxm1 expression in prostate epithelial cells is
essential for prostate carcinogenesis. J Biol Chem.
288:22527–22541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ketola K, Munuganti RSN, Davies A, Nip KM,
Bishop JL and Zoubeidi A: Targeting prostate cancer subtype 1 by
forkhead box M1 pathway inhibition. Clin Cancer Res. 23:6923–6933.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kim MY, Jung AR, Kim GE, Yang J, Ha US,
Hong SH, Choi YJ, Moon MH, Kim SW, Lee JY and Park YH: High FOXM1
expression is a prognostic marker for poor clinical outcomes in
prostate cancer. J Cancer. 10:749–756. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zavadil J and Bottinger EP: TGF-beta and
epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sahlgren C, Gustafsson MV, Jin S,
Poellinger L and Lendahl U: Notch signaling mediates
hypoxia-induced tumor cell migration and invasion. Proc Natl Acad
Sci USA. 105:6392–6397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Giannoni E, Bianchini F, Calorini L and
Chiarugi P: Cancer associated fibroblasts exploit reactive oxygen
species through a proinflammatory signature leading to epithelial
mesenchymal transition and stemness. Antioxid Redox Signal.
14:2361–2371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu
YH, Sung JS, Cha TL and Sun GH: Tumor-derived tumor necrosis
factor-alpha promotes progression and epithelial-mesenchymal
transition in renal cell carcinoma cells. Cancer Sci. 99:905–913.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sullivan NJ, Sasser AK, Axel AE, Vesuna F,
Raman V, Ramirez N, Oberyszyn TM and Hall BM: Interleukin-6 induces
an epithelial-mesenchymal transition phenotype in human breast
cancer cells. Oncogene. 28:2940–2947. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
St John MA, Dohadwala M, Luo J, Wang G,
Lee G, Shih H, Heinrich E, Krysan K, Walser T, Hazra S, Zhu L, et
al: Proinflammatory mediators upregulate snail in head and neck
squamous cell carcinoma. Clin Cancer Res. 15:6018–6027. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jiang J, Tang YL and Liang XH: EMT: A new
vision of hypoxia promoting cancer progression. Cancer Biol Ther.
11:714–723. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Park SY, Kim YJ, Gao AC, Mohler JL, Onate
SA, Hidalgo AA, Ip C, Park EM, Yoon SY and Park YM: Hypoxia
increases androgen receptor activity in prostate cancer cells.
Cancer Res. 66:5121–5129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mabjeesh NJ, Willard MT, Frederickson CE,
Zhong H and Simons JW: Androgens stimulate hypoxia-inducible factor
1 activation via autocrine loop of tyrosine kinase
receptor/phosphatidylinositol 3′-kinase/protein kinase B in
prostate cancer cells. Clin Cancer Res. 9:2416–2425.
2003.PubMed/NCBI
|
|
63
|
Geng H, Xue C, Mendonca J, Sun XX, Liu Q,
Reardon PN, Chen Y, Qian K, Hua V, Chen A, et al: Interplay between
hypoxia and androgen controls a metabolic switch conferring
resistance to androgen/AR-targeted therapy. Nat Commun. 9:49722018.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Amarilio R, Viukov SV, Sharir A,
Eshkar-Oren I, Johnson RS and Zelzer E: HIF1alpha regulation of
Sox9 is necessary to maintain differentiation of hypoxic
prechondrogenic cells during early skeletogenesis. Development.
134:3917–3928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bae KM, Dai Y, Vieweg J and Siemann DW:
Hypoxia regulates SOX2 expression to promote prostate cancer cell
invasion and sphere formation. Am J Cancer Res. 6:1078–1088.
2016.PubMed/NCBI
|
|
66
|
Xia LM, Huang WJ, Wang B, Liu M, Zhang Q,
Yan W, Zhu Q, Luo M, Zhou ZZ and Tian DA: Transcriptional
up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1.
J Cell Biochem. 106:247–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang GL and Semenza GL: Purification and
characterization of hypoxia-inducible factor 1. J Biol Chem.
270:1230–1237. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
